Production (Stage)
Harvard Bioscience, Inc.
HBIO
$0.2843
-$0.089-23.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -11.33% | 11.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.33% | 11.77% | |||
| Cost of Revenue | -8.68% | 14.09% | |||
| Gross Profit | -13.31% | 10.10% | |||
| SG&A Expenses | 1.46% | -5.20% | |||
| Depreciation & Amortization | -7.72% | -5.77% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.90% | 1.83% | |||
| Operating Income | -453.81% | 127.08% | |||
| Income Before Tax | -8,709.15% | 113.14% | |||
| Income Tax Expenses | -179.37% | 83.92% | |||
| Earnings from Continuing Operations | -279,766.67% | 100.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -279,766.67% | 100.37% | |||
| EBIT | -453.81% | 127.08% | |||
| EBITDA | -98.60% | 1,749.17% | |||
| EPS Basic | -285,500.00% | 100.36% | |||
| Normalized Basic EPS | -211.43% | 156.63% | |||
| EPS Diluted | -285,500.00% | 100.36% | |||
| Normalized Diluted EPS | -213.70% | 155.50% | |||
| Average Basic Shares Outstanding | 1.00% | 0.10% | |||
| Average Diluted Shares Outstanding | -0.81% | 1.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||